Genmab A/S
Genmab A/S is a biotechnology company focused on antibody therapeutics, with minimal direct political exposure evidenced by $0 federal contracts, $0 lobbying spend, and only one $350 doctor payment in 2024.
BusinessWhat GMAB does
Genmab A/S is a biotechnology company that develops and commercializes antibody therapeutics for cancer and other diseases. Its revenue is derived from collaborations, licensing, and product sales. The company operates in the healthcare sector with a market cap of approximately $18 billion.
12 months past · 3 months futureGMAB activity timeline
Lifetime Government AwardsGMAB federal contracts
GMAB doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding GMAB
Politicians Trading GMABMembers of Congress with recent GMAB positions
Congressional TradesWho in Congress is trading GMAB
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting GMABLive legislation impacting this stock
Political ProfileWhere GMAB sits in Washington
[object Object]
STRUCTURAL: No lobbying spend, no federal contracts, no donations. EVIDENTIARY: No insider buys, no congressional trades, only one small doctor payment. Net: Minimal direct political engagement, but subject to general healthcare regulation.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
General healthcare regulatory scrutinyFDA"Recent bill_impacts array shows multiple healthcare bills with low but non-zero impact_ratios, indicating regulatory exposure."
Regulatory opportunities
-
Potential favorable legislation for healthcare sectorCongress"Recent bill_impacts array shows bills with positive estimated revenue impact, though small relative to market cap."
Live signals + predictions for GMAB — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades GMAB
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord